October GLP-1 Recall Headlines: THE FACTS
A factual look at two compounded GLP-1 recall events: what was recalled, what reported quantities mean, why market share cannot be calculated reliably and what patients should check.
Share
Headlines get attention. The FACTS matter. Here’s what the FDA records say about these recalls, what remains unknown, and the sources you can check for yourself.
What was recalled?
Apothecary Pharma initiated a recall of certain compounded tirzepatide 18 mg/mL multidose vials on September 24, 2026. FDA lists 22 vials, each containing 4 mL. That means 22 multidose vials, not 22 patients or 22 doses. [1]
Carolina Infusion initiated a separate recall event on September 10, 2026. Its FDA record includes eight GLP-1 product entries involving semaglutide, tirzepatide and formulations combined with vitamin B12, at several concentrations. Most quantities are reported in milliliters; one entry lists eight 0.1 mL syringes. Eight product entries does not mean eight patients. [2]
Both events cite lack of sterility assurance. These notices concern specified compounded products and lots, not a blanket recall of Ozempic, Wegovy, Mounjaro or Zepbound. The exact pharmacy, formulation, concentration and lot number determine whether a notice applies to your medication.
These are two selected events, not a complete count of every GLP-1 recall in 2026. The FDA dataset reviewed was updated October 14, 2026, and listed both events as ongoing. Check current recall information before relying on that snapshot.
What percentage of the market was affected?
We could not verify a reliable percentage.
To calculate one, we would need a comparable total for the same market, time period and unit of measurement. Are we counting all GLP-1 prescriptions or only compounded injections? Vials, doses or patients? The recall records do not supply that denominator.
Adding different concentrations and medications together, or comparing multidose vials with prescriptions, would produce a number that looks precise without answering the question. The records also do not establish the number of unique patients affected. We should not call these recalls a “tiny share” of the market or use their reported quantities as proof of safety.
What does Class II mean?
FDA classified these recalls as Class II on October 8. In FDA’s definition, that category covers a situation that may cause temporary or medically reversible harm, or where the probability of serious harm is remote. It is not a declaration that a product is harmless, and it does not give a numerical risk for an individual patient. [3]
“Lack of sterility assurance” is also not the same as proof that every vial was contaminated. These records do not establish that every unit caused harm or that no harm occurred. For an injectable medication, uncertainty about sterility still warrants taking the recall seriously.
Were these products made overseas?
The recalls involve U.S.-based firms. The recall records do not identify where the active ingredients originated. A U.S. business address does not establish a wholly U.S.-sourced supply chain, and these records do not support claiming that the ingredients came from China. Geography alone is not a quality guarantee. [1, 2]
What should patients check?
Keep your medication’s original packaging and label. Ask the dispensing pharmacist to check the exact drug, concentration, lot number and beyond-use date against the recall. If a recall might apply, contact the pharmacy before using another dose. Follow confirmed recall instructions and ask your prescriber about an alternative. Seek urgent medical care for severe or rapidly worsening symptoms.
Compounded drugs are not FDA-approved; FDA does not review them for safety, effectiveness or quality before marketing. Knowing who prepared and dispensed your prescription helps you investigate a concern, but does not eliminate risk. [4]
Where Bliss Mist Rx fits
Bliss Mist Rx coordinates care; we do not compound medications ourselves. Our medications are compounded by pharmacies near Houston, Texas, and in the Santa Cruz area of California. Patients should still know which pharmacy prepared and dispensed their individual prescription. Our pharmacy-selection guide explains useful questions to ask.
These GLP-1 recalls do not establish the safety of ketamine or any other treatment. Compounded ketamine or ketamine/oxytocin sprays, IV racemic ketamine and FDA-approved intranasal esketamine are different treatments. Evidence and safeguards are not interchangeable. FDA warns of compounded ketamine risks including sedation, dissociation, breathing problems and misuse; at-home use lacks onsite monitoring. [5, 6]
The takeaway
Take recalls seriously without assuming a headline tells the whole story. Check the exact product, ask the pharmacist and separate documented facts from what remains unknown.
Related reading
Choosing a Pharmacy for Prescription Ketamine: Questions That Matter